Motley Fool Press Release.
Wave Life Sciences (WVE) delivered earnings and revenue surprises of +11.77% and +342.29%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Wave Life Sciences (WVE) stock jumps as the FDA backs a registrational pathway for WVE-006, a treatment for alpha-1 antitrypsin deficiency. Read more here.
Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers WVE-006 (RNA editing) has potential to offer the AATD community a new standard-of-care treatment to protect the liver and lung with a safe and convenient therapy CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad
Wave Life Sciences (WVE) has an average rating of buy and mean price target of $19.94, according to
Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that as part of the companies’ research collaboration, GSK has selected a candidate for a hepatology
Wave Life Sciences (WVE) said Wednesday that GSK (GSK) selected a liver disease drug candidate from
Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Monika Vnuk, MD, as Chief Business Officer. Dr. Vnuk will join Wave’s executive team and lead business development, corporate de
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Cantor 2026 Global Healthcare Conference in New York City on Thursday, September 10, 2026 at 9:45 a.m. ET. A live webcast of the present
This is the newest page. Registered accounts read further back.